10-K/A: Quipt Home Medical Details Governance, Compensation in 10-K/A

Quipt Home Medical Corp. files an amended annual report to disclose corporate governance, executive compensation, and beneficial ownership details, confirming a pending acquisition at US$3.65 per share.

Summary

• This Amendment No. 1 to the Annual Report on Form 10-K for the fiscal year ended September 30, 2025, provides information previously omitted regarding Part III items and new Section 302 certifications.
• The amendment explicitly states it does not modify or update the financial position, results of operations, or cash flows contained in the Original Form 10-K.
• The aggregate market value of voting and non-voting common shares held by non-affiliates was $90,853,438 as of March 31, 2025.
• There were 44,329,972 common shares outstanding as of January 23, 2026.
• The Board of Directors consists of four members: Gregory Crawford (President, CEO, and Director), Mark Greenberg (Director), Kevin Carter (Director), and Brian Wessel (Director).
• Executive compensation for fiscal year 2025 included total compensation of $3,043,176 for CEO Gregory Crawford, $1,473,957 for CFO Hardik Mehta, and $529,991 for CAO Thomas Roehrig.
• The company has an active 2024 Equity Incentive Plan (EIP) with a maximum of 8,420,494 common shares reserved for issuance, and 2,903,753 common shares were awarded under the EIP in fiscal year 2025.
• Employment agreements for the CEO and CFO include initial base salaries of $736,160 and $624,000, respectively, with a minimum 7% annual increase, and provisions for annual discretionary bonuses up to 100% of base salary.
• A cash transaction completion bonus of $912,500 is payable to CFO Hardik Mehta upon successful completion of the Arrangement.
• The company entered into an Arrangement Agreement on December 14, 2025, to be acquired by Purchaser for US$3.65 per share, with key securityholders agreeing to vote in favor.
• Audit fees billed by BDO were $890,183 for fiscal year 2025 and $993,823 (including audit-related fees) for fiscal year 2024.

Sentiment

Score: 7

Explanation: The filing provides comprehensive and transparent details on corporate governance, executive compensation, and beneficial ownership, which is positive for investor clarity. The confirmation of a pending acquisition at a fixed price offers a clear, expected outcome for shareholders. While related party transactions are noted, they are subject to Audit Committee review. No negative financial updates are presented, as the filing's scope is limited to non-financial disclosures.

Positives

• The company has a robust corporate governance framework with independent Audit, Compensation, and Nominating Committees.
• Brian Wessel, Chair of the Audit Committee, is qualified as an audit committee financial expert under SEC rules.
• The company has implemented a Clawback Policy for erroneously awarded incentive compensation, aligning with Rule 10D-1 of the Exchange Act.
• Insider trading and hedging policies are in place to promote compliance and prevent speculative trading by insiders.
• Executive compensation programs are designed to attract and retain qualified executives, motivate team performance, and align interests with shareholders through equity-based incentives.
• The pending acquisition at US$3.65 per share provides a clear and defined exit strategy for shareholders, with key securityholders already committed to voting in favor.

Negatives

• The Board of Directors, due to its small size (four members), has not adopted a formal written mandate.
• There is no formal orientation or continuing education program for new Board members, relying instead on an ad hoc and informal basis.
• The Board has not adopted specific targets for gender or underrepresented minority diversity, believing arbitrary targets are not in the best interests of the Corporation or its shareholders.
• The company does not have a retirement policy or established term limits for directors, citing potential loss of experienced talent.
• Related party transactions exist in the form of leases with an entity beneficially owned by the CEO, though these are subject to Audit Committee review.

Risks

• The Board oversees cybersecurity risks and major financial risk exposures, indicating these are ongoing concerns for the company.
• The Compensation Committee reviews incentive compensation arrangements to determine if they encourage excessive risk-taking, suggesting this is a potential area of concern.
• The Board's view that arbitrary director term limits could lead to losing experienced talent implies a risk associated with board renewal and succession planning.
• Conflicts of interest are a heightened risk in transactions between the Corporation and related persons, necessitating review and approval by the Audit Committee.
• The pending Arrangement Agreement for acquisition carries execution risk until its consummation, including potential for deal failure or delays.

Future Outlook

The primary forward-looking statement is the pending acquisition of Quipt Home Medical Corp. by Purchaser for US$3.65 per share, as detailed in the Arrangement Agreement. The company's compensation strategy is designed to optimize returns to shareholders and attract and retain high-quality executives.

Management Comments

• Gregory Crawford, CEO: 'spearheaded a transformative restructuring, revitalizing the company's operations and strategic direction. Under his leadership, the Corporation has experienced significant growth, expanding from $50 million to a multi-hundred-million-dollar revenue business.'
• Hardik Mehta, CFO: 'has developed a deep understanding and has mastered both financial and operational aspects of the HME/DME industry.'
• The Board believes that its current leadership structure, combining the Chairman and Chief Executive Officer roles with an independent Lead Independent Director, is appropriate at this time.
• The Board believes that arbitrary targets for diversity are not in the best interests of the Corporation or its shareholders, and is committed to nominating the best individuals as directors.
• The Board is of the view that the imposition of arbitrary director term limits may diminish the benefits derived from continuity amongst members and their familiarity with the Corporation and the industry.

Industry Context

Quipt Home Medical operates in the durable medical equipment (DME) industry, a sector that often sees consolidation. The company's reported growth from $50 million to a multi-hundred-million-dollar revenue business under current leadership suggests strong performance and strategic positioning within this competitive healthcare niche. The pending acquisition by REM Aggregator, LLC indicates ongoing M&A activity and strategic interest in the HME/DME market.

Comparison to Industry Standards

• The Compensation Committee reviews compensation paid to directors and executive officers of companies of similar size and stage of development in the healthcare industry to determine appropriate compensation levels, suggesting a benchmark-driven approach.
• The company's overall compensation objectives are stated to be in line with its peer group of healthcare companies, which similarly provide for opportunities to participate in equity ownership.

Management Changes

Corporate Governance

Related Party Transactions

• Six market rate leases for office, warehouse, and retail space are held with Greg Crawford, LLC, a rental company 100% beneficially owned through a trust over which Gregory Crawford (CEO and Chairman) exercises control and direction.
• Five of these leases were renewed in December 2022 for seven-year terms, with payments of approximately $65,000 per month and annual increases (greater of CPI-U or 3%).
• One lease expires in June 2026, and the remaining five expire on September 30, 2029.
• The aggregate amount of all periodic payments due on these leases was $3,807,159 for fiscal year 2025 and $4,566,725 for fiscal year 2024.
• The Audit Committee is responsible for reviewing and approving related party transactions to ensure fairness and consistency with the best interests of the Corporation and its shareholders.

Stakeholder Impact

• **Shareholders**: The pending acquisition at US$3.65 per share provides a clear and expected return on investment. Enhanced transparency in corporate governance and executive compensation offers greater insight into company operations.
• **Executives and Employees**: Executive compensation packages, including base salaries, performance incentives, equity awards, and retention bonuses, are detailed. The 2024 Equity Incentive Plan aligns employee interests with shareholder value. Employment agreements provide stability and severance provisions.
• **Customers and Suppliers**: Not directly addressed in this amendment, but the company's continued operations and growth in the DME industry imply ongoing relationships and service delivery.
• **Regulatory Bodies**: The filing demonstrates compliance with SEC and Canadian Securities Administrators' disclosure requirements, including Sarbanes-Oxley certifications and detailed corporate governance reporting.

Next Steps

• A special meeting of the Corporation will be held to vote on the Arrangement Agreement and the acquisition.
• Discretionary cash bonuses for the fiscal year ended September 30, 2025, if any, are expected to be determined in a subsequent period and disclosed in a Form 8-K filing.
• Restricted Share Units (RSUs) will vest in equal amounts on December 23, 2025, March 23, 2026, June 23, 2026, September 23, 2026, December 23, 2026, and March 23, 2027.
• Options for Thomas Roehrig to purchase 2,500 Common Shares will vest on November 20, 2025, and February 20, 2026.

Key Dates

Recommendation

The filing confirms the company's pending acquisition at a fixed price of US$3.65 per share, with key shareholders already committed to supporting the deal. For investors, this establishes a clear ceiling for the stock price. A 'hold' recommendation is appropriate for existing shareholders who wish to realize the acquisition price, assuming the current market price is at or below this offer. There is no new information in this amendment that would fundamentally alter the investment thesis beyond the confirmed acquisition.

Keywords

Quipt Home Medical, 10-K/A, SEC filing, corporate governance, executive compensation, beneficial ownership, Sarbanes-Oxley, SOX, audit committee, compensation committee, nominating committee, equity incentive plan, merger, acquisition, DME, durable medical equipment, related party transactions